Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.525
Journals
Pharmaceutics
Special Issues
Tropical Protozoan Disease Treatment Drugs
share announcement

Special Issue "Tropical Protozoan Disease Treatment Drugs"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 20 September 2023 | Viewed by 1759

Special Issue Editors

Dr. Rubén Martín-Escolano

E-Mail Website
Guest Editor
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Interests: antiprotozoal activity; chemotherapy; drug discovery; treatment schedule; tropical infectious diseases
Dr. Encarnación Medina Carmona

E-Mail Website
Guest Editor
Department of Physical Chemistry, University of Granada, Granada, Spain
Interests: drug discovery; drug design; chemotherapy; pharmacokinetics; treatment schedule
Prof. Dr. Clotilde Marín Sánchez

E-Mail Website
Guest Editor
Department of Parasitology, University of Granada, Granada, Spain
Interests: antiprotozoal activity; chemotherapy; drug discovery; protozoan parasites; tropical infectious diseases

Special Issue Information

Dear Colleagues,

Tropical diseases caused by protozoan parasites – such as Trypanosoma cruzi, Trypanosoma brucei, Leishmania spp. or Plasmodium spp., among others – affect million of people worldwide, causing more than a million human deaths and disabilities annually and high economic and social burden.

These pathogens have complex life cyles involving different morphological stages, sometimes within different vertebrate and invertebrate hosts. In addition, the diseases caused by these pathogens leads to complex pathology and long-term nature.

Many current drugs to combat these diseases have several disadvantages such as limited efficacy, severe side effects, requirement for long treatment periods, development of resistance, and high cost. Therefore, the search for new drugs and therapeutic strategies to combat these pathogens are urgently required.

Authors are kindly invite to submit original papers, communications and reviews regarding drug design, drug discovery, drug delivery, pharmacokinetics, pharmacodinamics and related topics, to be published in this Special Issue of Pharmaceutics.

Dr. Rubén Martín-Escolano
Dr. Encarnación Medina Carmona
Prof. Dr. Clotilde Marín Sánchez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiprotozoal activity
  • chemotherapy
  • drug delivery
  • drug design
  • drug discovery
  • pharmacodinamics
  • pharmacokinetics
  • protozoan parasites
  • treatment schedule
  • tropical infectious diseases

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

get_app
Article
The Bioactivity of Xylene, Pyridine, and Pyrazole Aza Macrocycles against Three Representative Leishmania Species
by
Álvaro Martín-Montes
,
Álvaro Martínez-Camarena
,
Alberto Lopera
,
Irene Bonastre-Sabater
,
M. Paz Clares
,
Begoña Verdejo
,
Enrique García-España
and
Clotilde Marín
Pharmaceutics 2023, 15(3), 992; https://doi.org/10.3390/pharmaceutics15030992 - 20 Mar 2023
Viewed by 581
Abstract
Due to the urgent need for finding effective and free of secondary effect treatments for every clinical form of Leishmaniasis, a series of synthetic xylene, pyridine and, pyrazole azamacrocycles were tested against three Leishmania species. A total of 14 compounds were tested against [...] Read more.
Due to the urgent need for finding effective and free of secondary effect treatments for every clinical form of Leishmaniasis, a series of synthetic xylene, pyridine and, pyrazole azamacrocycles were tested against three Leishmania species. A total of 14 compounds were tested against J774.2 macrophage cells which were models for host cells, and against promastigote and amastigote forms of each studied Leishmania parasite. Amongst these polyamines, one proved effective against L. donovani, another one for L. braziliensis and L. infantum, and another one was selective solely for L. infantum. These compounds showed leishmanicidal activity and reduced parasite infectivity and dividing ability. Action mechanism studies gave a hint that compounds were active against Leishmania due to their ability to alter parasite metabolic pathways and reduce (except Py33333) parasitic Fe-SOD activity. Full article
(This article belongs to the Special Issue Tropical Protozoan Disease Treatment Drugs)
►▼ Show Figures

Graphical abstract

get_app
Article
Identification of Aryl Polyamines Derivatives as Anti-Trypanosoma cruzi Agents Targeting Iron Superoxide Dismutase
by
Rubén Martín-Escolano
,
Daniel Molina-Carreño
,
Javier Martín-Escolano
,
Mª Paz Clares
,
Cristina Galiana-Roselló
,
Jorge González-García
,
Nuria Cirauqui
,
José M. Llinares
,
María José Rosales
,
Enrique García-España
and
Clotilde Marín
Pharmaceutics 2023, 15(1), 140; https://doi.org/10.3390/pharmaceutics15010140 - 31 Dec 2022
Viewed by 891
Abstract
Chagas disease (CD) is a tropical and potentially fatal infection caused by Trypanosoma cruzi. Although CD was limited to Latin America as a silent disease, CD has become widespread as a result of globalization. Currently, 6–8 million people are infected worldwide, and [...] Read more.
Chagas disease (CD) is a tropical and potentially fatal infection caused by Trypanosoma cruzi. Although CD was limited to Latin America as a silent disease, CD has become widespread as a result of globalization. Currently, 6–8 million people are infected worldwide, and no effective treatment is available. Here, we identify new effective agents against T. cruzi. In short, 16 aryl polyamines were screened in vitro against different T. cruzi strains, and lead compounds were evaluated in vivo after oral administration in both the acute and chronic infections. The mode of action was also evaluated at the energetic level, and its high activity profile could be ascribed to a mitochondria-dependent bioenergetic collapse and redox stress by inhibition of the Fe-SOD enzyme. We present compound 15 as a potential compound that provides a step forward for the development of new agents to combat CD. Full article
(This article belongs to the Special Issue Tropical Protozoan Disease Treatment Drugs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop